Whole-Body Photobiomodulation Therapy for Fibromyalgia: A Feasibility Trial

Dr B.C. Fitzmaurice1,2, Dr N.R. Heneghan2, Dr A.T.A. Rayen1, R. L. Grenfell3, Dr A. Soundy2

1Department of Pain Management, Sandwell and West Birmingham NHS Trust, Birmingham, UK
2School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, UK
3Clinical Research Facility, Sandwell and West Birmingham NHS Trust, Birmingham, UK

Bethany C Fitzmaurice1*
1Department of Pain Management, Sandwell and West Birmingham NHS Trust, Birmingham City Hospital, Dudley Road, Birmingham, B18 7QH, UK
Email: bfitzmaurice@nhs.net
Telephone: +44(0)121 507 4344

Nicola R Heneghan2
2School of Sport, Exercise and Rehabilitation Sciences, College of Life and Environmental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK

Asius TA Rayen1
1Department of Pain Management, Sandwell and West Birmingham NHS Trust, Birmingham City Hospital, Dudley Road, Birmingham, B18 7QH, UK

Rebecca L Grenfell3
3Clinical Research Facility, Sandwell and West Birmingham NHS Trust, Sandwell General Hospital, Lyndon, West Bromwich, B711 4HJ, UK

Andrew A Soundy2
2School of Sport, Exercise and Rehabilitation Sciences, College of Life and Environmental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK

*Corresponding author

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Abstract

Effective treatment for fibromyalgia (FM) is lacking and further treatment options are needed. Photobiomodulation therapy (PBMT) represents one potential treatment option. Whilst favourable findings have been reported using localised PBMT, no investigations have established the value of whole-body PBMT for the complete set of symptom domains in FM. A single-arm feasibility study was conducted in accordance to CONSORT guidelines. A non-probability sampling method was used to access individuals with FM. The primary outcome measure was identified as the Revised Fibromyalgia Impact Questionnaire (FIQR). Forty-nine participants were screened and 21 trial participants entered the trial. Nineteen participants completed the intervention (18 whole-body PBMT sessions over approximately six weeks). Descriptive statistics and qualitative analysis was undertaken to represent feasibility outcomes. Acceptability of the trial device and processes were established. Outcome measures towards efficacy data were guided by core and peripheral OMERACT domains, utilising a combination of participant-reported and performance-based outcome measures. Positive changes were observed for FM-specific quality of life, pain, tenderness, stiffness, fatigue, sleep disturbance, anxiety, depression and cognitive impairment. Patient global assessment revealed improvements at 6 weeks, with continued effect at 24 weeks. FM-specific quality of life at 24 weeks remained improved compared with baseline scores. Data for the embedded qualitative component of the trial were captured by participant-reported experience measures and audio-recorded semi-structured interviews. Findings provide evidence to support a full-scale trial and shows promise regarding potential efficacy of this novel non-invasive treatment in an FM population.

1. Introduction

Fibromyalgia (FM) syndrome is a multisystem disorder characterised by a vast array of symptoms; principally generalised body pain, fatigue, sleep and mood disturbance, and impaired cognition [99]. Physical, emotional and cognitive functioning is significantly lower in FM patients compared with their age- and gender-matched counterparts [58,101]. It is the second most common rheumatological condition [50] and lifetime worldwide prevalence is 6.8% - 15% [84].

In addition to significant patient burden and direct medical costs, FM has major socioeconomic impact with considerable indirect costs such as lost work productivity and disability benefits. A large US epidemiological study demonstrated annual healthcare costs being three times higher in FM patients compared with age- and gender-matched controls ($9,573 vs $3,291, respectively) [12]. A Canadian study revealed that less than half of FM patients were in employment, and of these, lost time from work due to FM symptoms was up to 4 weeks annually [72]. There is no cure for FM and long-term outcome data is limited – evidence shows chronicity to span at least seven years, and often much longer [3].
There is no known effective treatment for chronic primary widespread pain conditions [126] like FM, likely owing to their multifactorial aetiology and presentation [68]. It is commonplace for affected individuals to try a multitude of therapies, often accompanied with side effects despite evidence of limited benefit [70,124]. The most recent National Institute for Health and Care Excellence (NICE) guidance [93] regarding chronic pain management advises against use of many commonly instituted pain medications and interventions. The paucity of strong recommendations in international guidelines [62,86,123] highlights a need to explore other therapeutic methods and modalities. NICE call for further treatment options to be made available [94], and identify photobiomodulation therapy (PBMT) as a promising and recommend further research [123].

PBMT is a safe, non-invasive low energy light (red and near infrared) therapy that is absorbed by endogenous chromophores to induce cellular changes [25,42,95]. Localised PBMT demonstrates positive results across a multitude of acute and chronic pain conditions [14,21,24,28,33,34,43,49,54,59,61,81,103,105,138]. National and international healthcare governing bodies recommend PBMT in treatment of cancer-related painful oral mucositis [95]. Conventionally delivered by a trained therapist using a small probe applied to specific painful areas, recent studies identified a need for larger probes and stipulate that novel delivery devices would be advantageous [28,138].

The development of whole-body devices has allowed participants to self-administer PBMT. The NovoTHOR® device (Fig. 1) delivers treatment to the whole body, requiring no specialist skills, and appearing less labour intensive and time-consuming [46]. Whole-body PBMT is a novel treatment modality with potential to address multiple aetiological mechanisms in patients experiencing chronic and diffuse pain. Co-existing features commonly include cognitive and emotional impairment and evidence is emerging that PBMT can aid in the treatment of these ailments [51].

The aim of this study was to investigate the feasibility of whole-body PBMT as a treatment option for reducing pain and pain-related co-morbidities in FM.
2. Methods

The following methods are laid out in accordance with the CONSORT (CONsolidated Standards of Reporting Trials) extension to pilot and feasibility trials guidance [41] and SPIRIT-PRO Extension (SPIRIT, Standard Protocol Items: Recommendations for Interventional Trials; PRO, Patient-reported outcomes) guidance [19].

2.1. Trial design

This was a single centre and single-armed feasibility trial with an embedded qualitative component. All study procedures took place at Sandwell General Hospital’s Clinical Research Facility (CRF). Ethics approval was granted by the Health Research Authority (HRA) and Health and Care Research Wales (HCRW) (278452) and Leicester Central Research and Ethics Committee (21/EM/0231); ClinicalTrials.gov trial registration number NCT05069363. In order that the intervention can be replicated when building on future research, the TIDieR checklist was utilised [56]. The trial was designed according to the OMERACT (outcomes measures in rheumatological clinical trials) hierarchy (Fig. 2) – with the rationale that it clearly highlights a comprehensive view of the multidimensional nature of chronic pain, and subsequently provides the researcher with systematic and reproducible guidance.
The innermost circle of the OMERACT hierarchy contains the ‘core’ set of domains – assessment of which are deemed to be essential in all FM clinical trials. The second concentric circle includes the outer core set of domains to be assessed in some but not all FM trials. The outermost circle includes the domains on the research agenda that may or may not be included in FM trials [87]. For the purposes of this study, any domain assessed that is not a ‘core’ domain has been labelled ‘peripheral’ domain. We assessed all but two (CSF biomarkers and functional imaging) domains.

2.2. Participants

From January to June 2022, a non-probability sample were recruited from the Department of Pain Management at Sandwell and West Birmingham Trust. Prospective participants were required to satisfy all inclusion criteria: widespread chronic pain of any origin (including axial pain, polyarthralgia, myofascial pain); able to provide informed written consent; ≥18 years; able to commit time to the trial treatment schedule of 6 weeks; score as low or moderate risk on the COVID-19 risk stratification tool – applicable for the duration of the pandemic. Exclusion criteria included: pregnancy; severe skin diseases (e.g. skin cancer, severe eczema, dermatitis, or psoriasis); body weight ≥136kg; uncontrolled co-morbidities (e.g. uncontrolled diabetes defined as HbA1c >69mmol/mol, decompensated heart failure, major psychiatric disturbance such as acute psychosis or suicidal ideation); use of systemic corticosteroid therapy including oral prednisolone or corticosteroid injections within the preceding 6 months; known active malignancy; inability to enter the NovoTHOR® device or lie flat for 20 minutes (either due to physical reasons or other e.g. claustrophobia); individuals speaking a...
language for which an interpreter cannot be sought (Oromo, Tigranian, Amharic, Greek). All participants gave written informed consent and were free to withdraw from study participation at any point.

2.3. Interventions

Screening of referred individuals was undertaken by the Principal Investigator (BF) via clinical records and a telephone call. A maximum of 5ml of blood was taken as part of the screening process to confirm normal blood profile prior to trial commencement. Questionnaires were self-administered on paper in the presence of a study investigator (see ‘Measures’ section). The study schedule is depicted in Figure 3 and Table 1, including an overview of events at each study visit.
**Figure 3.** CONSORT study flow diagram.

**Screening**
Prior to eligibility assessment

**Enrolment**
Telephone call for eligibility & risk assessment

**Baseline Visit**
- Consent
- Medical history and demographics
- Blood tests
- Measurements

**First Visit**
- Measurements, Examination, Questionnaires, 1st treatment
- Interviews, if applicable

**Intervention**
3x / week for 6 weeks
(Visit 2 – Visit 17)

**Final Visit**
- Treatment 18
- Questionnaires
- Examination
- Interviews, if applicable

**Follow-Up Call**
Questionnaires

**Screening**
Prior to eligibility assessment

**Enrolment**
Telephone call for eligibility & risk assessment

**Baseline Visit**
- Consent
- Medical history and demographics
- Blood tests
- Measurements

**First Visit**
- Measurements, Examination, Questionnaires, 1st treatment
- Interviews, if applicable

**Intervention**
3x / week for 6 weeks
(Visit 2 – Visit 17)

**Final Visit**
- Treatment 18
- Questionnaires
- Examination
- Interviews, if applicable

**Follow-Up Call**
Questionnaires
Table 1. Outline of study procedures.

<table>
<thead>
<tr>
<th>Procedures</th>
<th>Telephone Call</th>
<th>Baseline Visit</th>
<th>First Visit</th>
<th>Visit 2-Visit 17</th>
<th>Final Visit</th>
<th>6-month Telephone Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligibility Assessment</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed consent</td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood Tests</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Full blood count, Urea and electrolytes, Liver function tests, HbA1c (if diabetic)</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, Gender, Marital status, Employment status, Educational level, Ethnicity</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical History</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic pain symptom duration, Co-morbidities, Medications</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measurements</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Height, Weight, BMI, Blood pressure, Heart rate, Oxygen saturations</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Participant-reported outcome measures (PROMs)

| Brief Pain Inventory | x              | x              |             | x              |             |                             |
| Widespread Pain Index/Symptom Severity Score | x              | x              |             | x              |             |                             |
| Fatigue Severity Scale | x              | x              |             | x              |             |                             |
| Jenkins Sleep Questionnaire | x              | x              |             | x              |             |                             |
| Patient Global Impression of Change | x              | x              |             | x              |             |                             |
| Revised Fibromyalgia Impact Questionnaire | x              | x              |             | x              |             |                             |
| Hospital Anxiety and Depression Scale | x              | x              |             | x              |             |                             |

**Performance-based outcome measures (PBOMs)

| Tender Point Count | x              |                |             |                 |             |                             |
| Stroop Test | x              | x              |             |                 |             |                             |
| Treatment |                | x              |             |                 |             |                             |
| Weekly Numerical Rating Scale (NRS) - applicable for preceding week |                |                |             |                 |             |                             |
| Participant-reported experience measure (PREM) |                |                |             |                 |             |                             |
| Audio-recorded qualitative interviews (optional) | x              | x              |             |                 |             |                             |

*Please see Table 4 for more detail

**Please see Table 5 for more detail
The trial intervention is exhibited in Table 2 and NovoTHOR® dosage parameters in Table 3.

Table 2. Template for intervention description and replication (TIDieR) checklist.

<table>
<thead>
<tr>
<th>BRIEF NAME</th>
<th>Whole-Body Photobiomodulation Therapy – 18 sessions</th>
</tr>
</thead>
</table>
| WHY         | Eighteen sessions are the currently recommended and widely instituted and accepted practice with the NovoTHOR® device.  
This device was developed in 2013, and since then 251 NovoTHOR® systems have been developed of which 217 systems are still in regular use, treating at least four patients per device per day. This equates to approximately 1.6 million treatments since its inception. No significant adverse events have been reported to date. |
| WHAT        | All participants entering the trial will receive a course of whole-body PBMT.  
The NovoTHOR® Whole-Body PBMT device consists of a hinged, clamshell design with light-emitting diodes (LEDs) arranged to emit near-infrared and visible red light → PBMT is delivered to the entire body at once.  
A Participant Information Sheet (PIS) will be provided at least 48 hours before participants are requested to consent to the study. They will be given the opportunity to undertake an experience session.  
Participants will be expected to lie horizontal in the device with the lid as closed as they are comfortable with. |
| WHO PROVIDED| All trial investigators, following a short training session in the use of NovoTHOR®. |
| HOW         | The LED equipment delivers red and near infrared light therapy to the participant (as per the settings illustrated in Table 2). |
| WHERE       | Clinical Research Facility, SWB Trust.  
Participants are registered at the Trust and are therefore geographically within the region.  
The device requires a well-ventilated, spacious, temperature-controlled room, with appropriate mains electricity. |
| WHEN and HOW MUCH | Session 1 = 6 minutes.  
Session 2 = 12 minutes.  
Sessions 3-18 = 20 minutes.  
Timescale: 3 treatments/week for 6 weeks.  
The dosage of LED light (also known as ‘fluence’) will be equivalent to 25J/cm². The device will supply a dual wavelength of red and near-infrared light with a 50:50 ratio; 660nm and 850nm respectively. |
| TAILORING   | After liaison with experienced clinicians within the field with experience dealing with our population in the NovoTHOR®, we decided to slowly uptitrate the treatment times during the first three treatments for all participants. |
| MODIFICATIONS | Described in ‘Results’ section. |
| HOW WELL    | Described in ‘Results’ section. |
Table 3. NovoTHOR® Parameters.

<table>
<thead>
<tr>
<th>NovoTHOR® Parameters</th>
<th>Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wavelengths of red and near-infrared (NIR) LEDs 50:50 ratio</td>
<td>660 nm, 850 nm</td>
</tr>
<tr>
<td>Number of LEDs</td>
<td>2,400</td>
</tr>
<tr>
<td>Power emitted per LED</td>
<td>0.289 W</td>
</tr>
<tr>
<td>Beam area per LED (at the lens/skin contact surface)</td>
<td>12.0 cm²</td>
</tr>
<tr>
<td>Total Power emitted</td>
<td>694 W</td>
</tr>
<tr>
<td>Total Area of NovoTHOR® emitting surfaces</td>
<td>26,740 cm²</td>
</tr>
<tr>
<td>Treatment Time</td>
<td>1200 s</td>
</tr>
<tr>
<td>Continuous Wave (CW) (not pulsed)</td>
<td>CW</td>
</tr>
<tr>
<td>Irradiance</td>
<td>0.028 W/cm²</td>
</tr>
<tr>
<td>Fluence</td>
<td>33.6 J/cm²</td>
</tr>
</tbody>
</table>

2.4. Outcomes

Eligibility criteria were explored by means of analysing eligibility rates. Refusal and retention rates were used to quantitatively assess acceptability. Qualitative interviews and participant-reported experience questionnaires were employed to evaluate the acceptability and practicability of the device, treatment schedule, trial design and appropriateness of outcome measures. OMERACT, established in 1992, is an international initiative to improve outcome measurement in rheumatology - affiliated with the International League for Rheumatology, World Health Organization, and the Cochrane Collaboration Musculoskeletal Review Group [127]. FM is a good example of diffuse and widespread pain, encompassing both axial and multi-joint pain. The OMERACT hierarchy was used to assess treatment efficacy according to symptom domains. A combination of participant-reported (Table 4) and performance-based (Table 5) measures were employed. The following participant-reported outcome measures have all demonstrated reliability and validity in the assessment of pain conditions [6,9,22,35,38,47,64,89,122]. Additionally, these tools are recognised as the recommended standardised assessment tools for FM domains by an international consortium of experts in the field [115]. Table 1 depicts the time points at which questionnaires were administered. Table 4 gives a brief description of each tool used to assess outcome measures.
### Table 4. Participant-reported outcome measures (PROMs).

<table>
<thead>
<tr>
<th>OMERACT domain</th>
<th>Outcome measure</th>
<th>Tool background, use and scoring</th>
<th>Tool administration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Core Domains</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multidimensional function</td>
<td>FIQR(^{(1)}) (2009, replacing FiQ)</td>
<td>Recommended outcome measure in assessment of ‘multidimensional function’ or health-related quality of life [16]. 21 questions across 3 domains: ‘function’, ‘overall impact’, ‘symptoms’. Each question requires a score based on an 11-point Numerical Rating Scale (NRS) pertaining to previous seven days, with a score of 0 being the ‘best’ and 10 being ‘worst’. Administrator calculates overall score. 9 questions from Domain 1 are totalled and divided by 3. 2 questions from Domain 2 are simply added. 10 questions from Domain 3 are totalled and divided by 2. The final sum of resulting 3 figures represents the total (0 to 100). Higher scores indicate increased severity of FM [11].</td>
<td>Time to complete: 3.5 minutes Number of administrations: 3 (First Visit, Final Visit, Follow-up telephone call)</td>
</tr>
<tr>
<td>Pain</td>
<td>BPI-SF(^{(2)}) (1994)</td>
<td>Distinguishes pain into two components in preceding 24h - pain intensity and pain interference [27]. The recommended pain assessment tool in FM clinical trials [16]. ‘Sensory dimension’: asked to rate ‘worst’, ‘least’, ‘average’, ‘pain now’ on 11-point NRS. ‘Reactive dimension’: score extent pain has interfered with mood, walking and other physical activity, work, social activity, relations with others, and sleep (0 = ‘does not interfere’, 10 = ‘completely interferes’) [27]. 4 pain-intensity and 7 pain-interference results averaged to give overall pain-intensity score and pain-interference score (0 to 10), respectively [4,26,75].</td>
<td>Time to complete: 3 minutes Number of administrations: 2 (First Visit, Final Visit)</td>
</tr>
<tr>
<td>Pain</td>
<td>WPI+SSS(^{(3)}) (2010, updated 2016)</td>
<td>Updated diagnostic tool and a potential alternative [131] to original tender point examination, 1990 [132]. WPI: tick painful anatomical areas in preceding week. 19 areas are listed across 5 anatomical regions; 4 of which need to be ‘positive’ for an initial diagnosis of FM to be met. SSS: scored out of maximum of 12. Encompasses array of symptoms - user asked to report their presence and/or severity. Total potential combined WPI-SSS score is 31 - higher scores indicate more severe FM [131]. Updated 2016 version: for user to be positive for FM diagnosis must score WPI ≥ 7 and SSS ≥ 5, or WPI 4-6 and SSS ≥ 9 [130].</td>
<td>Time to complete: 4 minutes Number of administrations: 2 (First Visit, Final Visit)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>FSS(^{(4)}) (1989)</td>
<td>Unidimensional generic fatigue rating scale [71], emphasises functional impact of fatigue [111]. The recommended fatigue assessment tool for FM [16]. 9 fatigue-related questions, each scored on a 7-point Likert agreement scale (1 to 7). Resultant score is average of 9 scores, with maximum possible score of 7 - indicating the most severe fatigue-related symptoms and intrusiveness.</td>
<td>Time to complete: 1.5 minutes Number of administrations: 2 (First Visit, Final Visit)</td>
</tr>
<tr>
<td>Sleep disturbance</td>
<td>JSQ(^{(5)}) (1988)</td>
<td>4-item self-report questionnaire designed to measure frequency of sleep problems in past month.</td>
<td>Time to complete: 1 minute</td>
</tr>
</tbody>
</table>

---

\(^{(1)}\) OMERACT (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
The recommended assessment tool to evaluate sleep in FM patients [16]. 5-point Likert scale (0 = 'not at all' to 5 = '22-31 days') utilised to evaluate the number of days/month that specific sleep-related issues occur (trouble falling and staying asleep, waking up several times/night, waking up after usual amount of sleep feeling tired and worn out). Maximum possible score is 20. Higher scores indicate higher frequency of sleep problems [63].

| Patient Global | PGIC\(^{(vi)}\) (1970s) | Self-report global change questionnaire: 7-point NRS (1 to 7) to determine degree of change following a treatment from patients’ own perspective. Score of ‘1’ indicates either no change or worsening symptoms since treatment. ‘7’ indicates the patient feels ‘great deal better, considerable improvement that has made all the difference’ [60]. IMMPACT (Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials) recommended for evaluating participant ratings of overall improvement in pain treatment trials [40]. Specifically recommended in the assessment of global improvement of FM patients in conjunction with the FIQR [16]. | Time to complete: 1 minute Number of administrations: 2 (Final Visit, Follow-up telephone call) |

| Peripheral Domains | Anxiety | HADS\(^{(vii)}\) (1983) Anxiety subsection (HADS-A) | 14-item measure: each item rated on a 4-point severity scale (0 to 3). HADS-A subscales: comprised of 7 items. Acknowledged to have been used in FM trials assessing medication efficacy [16]. | Time to complete: 1 minute Number of administrations: 2 (First Visit, Final Visit) |
| | Depression | HADS\(^{(vii)}\) Depression subsection (HADS-D) | HADS-D subscales: comprised of 7 items. Scores range from 0 to 21. Higher scores indicate more severe symptoms [118,138]. The recommended tool for assessment of depressive symptoms in FM patients [16]. | Time to complete: 1 minute Number of administrations: 2 (First Visit, Final Visit) |
| | Stiffness | | Time to complete: N/A Number of administrations: 3 (First Visit, Final Visit, Follow-up telephone call) |
| | Dyscognition | | Time to complete: N/A (subsection of FIQR) Number of administrations: 3 (First Visit, Final Visit, Follow-up telephone call) |
| | | Total completion time: 16 minutes |

\(^{(i)}\) FIQR (Revision Fibromyalgia Impact Questionnaire) \n\(^{(ii)}\) BPI-SF (Brief Pain Inventory – Short Form) \n\(^{(iii)}\) WPI+SSS (Widespread Pain Index, Symptom Severity Score) \n\(^{(iv)}\) FSS (Fatigue Severity Scale) \n\(^{(v)}\) JSQ (Jenkins Sleep Questionnaire) \n\(^{(vi)}\) PGIC (Patient Global Impression of Change) \n\(^{(vii)}\) HADS (Hospital Anxiety and Depression Score)
Table 5. Performance-based outcome measures (PBOMs).

<table>
<thead>
<tr>
<th>OMERACT domain</th>
<th>Outcome measure</th>
<th>Tool background, use and scoring</th>
<th>Tool administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Core domains</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tenderness</td>
<td>Tender point examination (1990)</td>
<td>Manual Tender Point Survey/Fibromyalgia Intensity Score (MTPS/FIS) method is validated for FM population [100]. The currently recommended tenderness assessment for FM trials [16]. 18 specific tender points (9 bilateral anatomical areas) identified by American College of Rheumatology in 1990 [133]. Assessed with hand-held Wagner FORCE TEN™ FDX pressure algometer - incremental increase up to a maximum of 4kg/cm². Pain severity rated at each point according to verbal NRS, with NRS ≥2 ‘positive’ for a tender point. Anatomical points: low cervical (C5-C7); 2nd rib (2nd costochondral junction); greater trochanter (posterior to trochanteric prominence); knee (at medial fat pad proximal to joint line); occiput (at suboccipital muscle insertions); trapezius (a midpoint of upper border), supraspinatus (above scapular spine near medial border), lateral epicondyle (2cm distal to epicondyles); gluteal (upper outer quadrants of buttocks in anterior fold of muscle).</td>
<td>Time to complete: 2 minutes Number of administrations: 2 (First Visit, Final Visit)</td>
</tr>
<tr>
<td>Peripheral domains</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyscognition</td>
<td>Stroop Test (1935 – original)</td>
<td>Selected in attempt to address the cognitive domains of inhibitory control, processing speed and memory; which have been shown to be the most significant cognitive complaints in the FM population [9]. The Stroop Test for Research application [98] is a computer-based test, performed via mobile application in the current study. A series of colours are spelt out on the screen; blue, red, yellow, green. Each time the word appears it is presented in a different colour; blue, red, yellow or green. Timed task over 60 seconds, user required to select correct colour of word. Scored by number of correct answers. No marks lost for incorrect answers.</td>
<td>Time to complete: 1 minute Number of administrations: 2 (First Visit, Final Visit)</td>
</tr>
</tbody>
</table>

Total completion time: 3 minutes

2.5. Sample size

Sample size was estimated based on CONSORT guidelines for feasibility studies; describing a primary evaluation that focuses on descriptive analysis of feasibility/process outcomes (e.g. recruitment, adherence, treatment fidelity) [41]. Data from previous work surrounding localised PBMT in FM was used to inform sample size [134]. Our chosen sample size takes into account the study populations’ number of visits at our clinics, study objectives, and recommendations for the sample size calculations in pilot and feasibility trials [69,73,78,90]. Sample size for the qualitative component was guided by the concept of information power [82]. Considering past research [117] looking at experiences of an intervention, we attempted to interview all participants.
2.6. Statistical methods

Feasibility data were assessed as the primary study outcomes. Descriptive statistics have been utilised to report these data. Secondary outcomes to assess treatment efficacy comprise participant-reported and performance-based outcome measures. Microsoft Excel (2019) was employed to calculate mean averages and confidence intervals of parametric data. All results presented are mean average values with corresponding population standard deviations (±SD). Objective tenderness is depicted by scatterplots. An overview of pre- and post-treatment scores for all domains will be presented visually by means of box and whisker plots. Medication changes are depicted in tabular format. Skewness and Kurtosis and confidence interval analyses performed via IBM SPSS Statistics Versions 28.0.1.1 and 29.0.0.0 were employed to confirm normal distribution of the future primary outcome measure (FIQR) prior to implementing Paired-Samples T test using SPSS. Cohen’s d effect sizes were calculated using an online calculator [115] for all outcome measures. Cohen’s d effect size for the primary outcome measure were then employed to inform the sample size for the future definitive RCT [29]. Qualitative data gathered from semi-structured interviews will undergo reflexive thematic analysis [18]. For the purpose of the study this analysis will be undertaken separately and inductively.

3. Results

3.1. Participant Flow

From January to June 2022 a total of 49 individuals were screened for potential enrolment onto the trial (Fig. 4). Of these 49, 42 met the eligibility criteria and 24 giving consent and were prepped to commence the trial treatment. From January 2022, a total of 21 participants commenced treatment with nineteen completing the treatment schedule by August 2022.
3.2. Recruitment

Recruitment was via two sources: (i) self-referral via recruitment posters in pain clinics and procedure areas (ii) clinician-referral from pain clinics and pain intervention lists. The trial was advertised between January and August 2022. The first participant underwent their first treatment on 31st January 2022, with the final participant entering the trial on 29th June 2022. All participants had completed their treatment by 10th August 2022. Six-month data collection was completed 3rd January 2023.
3.3. Baseline Data

All participants had clinician-diagnosed FM. Symptoms duration ranged from 4 to 31 years, with an age range of 28 to 66 years (14, 70% female; 6, 30% male). All but one male participant received 18 treatments. Further demographics and characteristics are shown in Table 6.

Table 6. Baseline demographic and clinical characteristics.

<table>
<thead>
<tr>
<th></th>
<th>n (%)</th>
<th>Mean±SD</th>
<th>Median (IQR)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>14 (70)</td>
<td>47.3±10.9</td>
<td>49 (41-53)</td>
</tr>
<tr>
<td>Male</td>
<td>6 (30)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td></td>
<td>47.3±10.9</td>
<td>49 (41-53)</td>
</tr>
<tr>
<td><strong>Symptom duration (years)</strong></td>
<td></td>
<td>15.6±7.7</td>
<td>14.5 (10-20)</td>
</tr>
<tr>
<td><strong>Marital status</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Married</td>
<td>10 (50)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single</td>
<td>6 (30)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Divorced</td>
<td>1 (5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-habiting</td>
<td>2 (10)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Civil partnership</td>
<td>1 (5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Employment status</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Employed full-time</td>
<td>4 (20)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Employed part-time</td>
<td>1 (5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Self-employed</td>
<td>2 (10)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unemployed (looking for work)</td>
<td>1 (5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unemployed (not looking for work)</td>
<td>7 (35)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sick leave</td>
<td>1 (5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retired</td>
<td>4 (20)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Education level</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Some secondary school</td>
<td>1 (5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Completed secondary school</td>
<td>2 (10)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Completed further education (sixth form)</td>
<td>1 (5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Higher education</td>
<td>16 (80)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ethnicity</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asian or Asian British</td>
<td>5 (25)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black British</td>
<td>1 (5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White British</td>
<td>14 (70)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Height (cm)</strong></td>
<td></td>
<td>166±10.1</td>
<td></td>
</tr>
<tr>
<td><strong>Weight (kg)</strong></td>
<td></td>
<td>87.9±19.1</td>
<td></td>
</tr>
<tr>
<td><strong>BMI (kg/m²)</strong></td>
<td></td>
<td>31.5±5.9</td>
<td></td>
</tr>
<tr>
<td><strong>Systolic blood pressure (mmHg)</strong></td>
<td></td>
<td>136±20.9</td>
<td></td>
</tr>
<tr>
<td><strong>Diastolic blood pressure (mmHg)</strong></td>
<td></td>
<td>86±10.9</td>
<td></td>
</tr>
<tr>
<td><strong>Heart rate</strong></td>
<td></td>
<td>79±12.0</td>
<td></td>
</tr>
<tr>
<td><strong>Oxygen saturations (%)</strong></td>
<td></td>
<td>98±1.0</td>
<td></td>
</tr>
</tbody>
</table>
3.4. Primary (feasibility) outcomes

Quantitative data related to feasibility outcomes and guiding a definitive RCT are expressed below.

3.4.1. Recruitment-related feasibility outcomes

3.4.1.1. Eligibility

Of the 25 participants that were excluded prior to consent, seven were excluded due to ineligibility; one became pregnant, two did not meet the inclusion criteria for pain type, two had received recent steroid injections, and two had uncontrolled co-morbidities. Throughout the recruitment period a considerable number of participants did not reach the screening phase due to having recently received steroids.

3.4.1.2. Barriers to uptake

Of the 18 participants that ‘declined to participate’, seven participants could not commit the time to the treatment schedule, three participants felt they would be too fatigued by the travel, one participant could not afford the petrol for the travel (lived more than 20 miles away), one participant was worried about personal unreliability due to unpredictability of flare ups, two participants were uncontactable, one participant had moved areas, one participant was actively trying to become pregnant, and one participant was claustrophobic. The latter participant came to try the device but could not enter the study due to physical discomfort in the device and claustrophobia. One participant was commenced on a course of oral steroids during the latter stages of her treatment schedule in order to treat a respiratory infection.

3.4.1.3. Trial retention

Of the three participants that consented but did not proceed; one participant became pregnant, one became uncontactable and one participant re-considered due to both taxi costs and getting to top of the list for a steroid injection for their pain condition, and did not wish to postpone this. Subsequent to commencing the treatment schedule, one participant exited the trial after four ad hoc treatments due to difficulty with committing to the treatment schedule. The other participant exited the trial after completing 17 treatments secondary to a reported road traffic collision. All participants (n=19) were contactable at 6-month follow up.
3.4.2. Trial-related feasibility outcomes

3.4.2.1. Provision of information prior to trial

All participants were satisfied with the level of information they received prior to commencing the trial. One participant (5.3%) felt a video demonstration of the device prior to visiting the hospital might be helpful.

3.4.2.2. Acceptability of treatment schedule

Twelve participants (63.1%) were satisfied with the number and frequency of treatment sessions. One participant was ‘not sure’ and the remaining six participants (31.6%) would like to see a change in the number and frequency of treatment sessions. Of the latter six, five participants expressed a preference towards more frequent treatments (daily), longer treatment duration, increased number of treatments over longer time period. The remaining participant felt three days per week was too many visits. The same participant found the expense of transport an obstacle.

3.4.2.3. Adherence to treatment schedule

For those participants who received the full treatment schedule, and the one participant receiving the majority of treatments, 50% participants (n = 10) received three treatments thrice weekly (Monday, Wednesday, Friday) for six weeks as scheduled. Ten participants were non-adherent with the treatment schedule. These participants received all 18 treatments spanning a duration of 7-9 weeks, over which time 41 visits were postponed. Twenty-five visits (61%) were missed on the scheduled day attributable to medical reasons; ‘fibro flare’ (n = 2), fall (n = 1), poor sleep (n = 2), viral symptoms (n = 5), covid19 (n = 7), migraine (n = 1), burning sensations behind cheekbones (n = 4), elective sinus surgery (n = 3). Practical reasons included lost car keys (n = 1), staffing and investigator availability (n = 3), dissatisfaction with travel expenses (n = 4), ‘Did Not Attend’ (n = 4), and ‘unforeseen circumstances’ (n = 1). Family reasons included daughter having surgery (n =1) and bereavement (n = 1). Work/study reasons included attending a course in Wales (n = 1).

3.4.2.4. Acceptability of travel and expenses

Single journey distance ranged from 0.6 miles to 9.6 miles (assuming the participant travelled from home). Participants were required to visit the Clinical Research Facility a total of 19 times during the course of the trial, summating in a mean average±SD of 181.45±87.85 (range 22.8 – 364.8 miles). Thirteen participants (65%) travelled by car, two by bus, one by motorbike/scooter, and one participant walked. Three participants
travelled via taxi, one of which was through choice due to anxiety of driving and parking. Of the three that travelled by taxi, two reported difficulties relating to funding their journey. In one case this led to missed appointments due to lack of funds, and the other participant who chose to come by taxi missed several appointments due to dissatisfaction relating to travel reimbursement.

3.4.2.5. Acceptability of participant-reported outcome measures

A total of 17 participants (89.5%) felt questionnaires administered were easy to follow and complete, with the remaining 10.5% (n = 2) being ‘not sure’. All participants (n = 19) felt the number and breadth of questionnaires was appropriate and necessary. Two participants (10.5%) felt more questionnaires were warranted to express further aspects of their condition impacting on their daily life. One participant felt that stiffness should have been measured objectively.

3.4.2.6. Acceptability of performance-based outcome measures

A total of 17 participants (89.5%) found the Stroop Test delivered via mobile application straightforward to use and understood what was being asked of them. One participant (5.3%) was ‘not sure’ as they had no memory of performing the test. All participants (n = 19) would be happy to complete further additional cognitive objective measures in a future trial. All participants (n = 19) felt the tender point examinations were necessary towards assessing their condition and all would be happy for the same examination in a future trial. However, participants admitted they did not want considerable pressure applied at Week 6 due to concerns over inducing a FM flare and no longer having the treatment available to aid this.

3.4.2.7. Acceptability of audio-recorded semi-structured interviews

Sixteen participants (84.2%) underwent audio-recorded semi-structured interviews. Fourteen of these participants found the interviews straightforward and felt comfortable. One participant did not answer and one participant felt a little uncomfortable due to not liking the sound of their voice.
3.4.3. Treatment-related feasibility outcomes

3.4.3.1. Acceptability of trial device

When asked to give comment about access and accessibility, six participants (31.6%) did not answer. The remaining 13 participants (68.4%) felt both the trial location and the device itself were easy to access. Constructive comments related to suggestion of a supporting rail for ease of entry and exit onto and off the device and a larger changing space. Two participants (10.5%) were asked to remove their transdermal fentanyl patch for every treatment. One participant managed to re-apply using adhesive dressings. The second participant required a temporary increase in quantity via prescription due to unsuccessful re-application of patches. All participants graded usability and comfort of trial device on a Likert scale from 1 = strongly agree through to 5 = strongly disagree (Fig. 5).

Figure 5. Participant experience of trial device.

3.4.3.2. Treatment satisfaction

Participants were asked to list three words to describe their experience of the ‘light therapy pod’. Positive experiences included: helpful (n=4), pleasant (n=3), positive (n=3), enjoyable (n=2), comfortable (n=1), efficient (n=1), great (n=1), useful (n=1), interesting (n=1), painless (n=1), quick (n=1), beneficial (n=1), easy (n=1), worthwhile (n=1), necessary (n=1). One negative experience was described with regards to pain impeding ability to make appointments: difficult (n=1). Low-energy positive emotions were: relaxing (n=11), calming (n=3) and soothing (n=2). High-energy positive emotions were: pain relief (n=4), warm (n=3), better memory (n=2), good mood (n=2), better sleep (n=1), more energy (n=1), less confused (n=1), reduced headaches (n=1), clearer mind (n=1), addictive (n=1), and fun (n=1). One future-related description was: hope (n=1).
3.4.4. Willingness towards future trial

All trial participants were willing to be involved in future research related to this device and all were happy with the prospect of a 50:50 chance of receiving 18 placebo treatments, selected at random, and being ‘blinded’ with goggles.

3.5. Secondary outcomes

Secondary outcomes are presented in accordance with the OMERACT Working Group for FM [87], with the rationale of evaluating potential efficacy of whole-body PBMT. A combination of the above-mentioned participant-reported and performance-based outcome measures were utilised to measure the six ‘core’ domains and four ‘peripheral’ domains. Standard deviations (SD) presented are with reference to sample SD. Figure 9 depicts a graphical representation of the median, mean, range and interquartile range for all outcome measures pre- and post-treatment. Confidence intervals and effect sizes for all outcome measures are demonstrated in Tables 7 and Table 8. Additionally, pain symptom-related medications and dosage changes post-treatment are reported.

3.5.1. Core domains: participant-reported outcome measures

3.5.1.1 Multidimensional function

Pre-treatment FIQR scores were 79.7±13.26. At Week 6 scores had reduced to 55.3±19.72 - an improvement of 24.44±20.38 points (p = <0.001). By Week 24, scores were 65.68±16.53; an increase compared with Week 6 (p = 0.23), but clinically [10] and statistically significantly (p = 0.001) lower compared with baseline scores (Fig. 6). FIQR score can be categorised by severity [10]. According to this scale, 17 participants (89.5%) commenced the trial with their FM symptoms having a severe effect on them and their symptoms being very intrusive. Six of the participants (37.5%) who commenced the trial with ‘severe’ FM (score ≥59 to 100), had only ‘moderate’ FM (score ≥39 to 59) after 6 weeks of PBMT, whilst four (25%) finished with treatment with ‘mild’ FM (score 0 to <39). Seven participants remained in the severe category, albeit, all with a lower post-treatment score.
Figure 6. Mean FIQR scores (y-axis) with 95% Confidence Intervals, at specified timepoints (x-axis).

3.5.1.2. Pain

Pre-treatment pain-intensity was 7.08±1.28. Post-treatment pain-intensity was 3.93±1.38. Pain-interference score improved to 4.17±1.99 from a pre-treatment score of 6.59±1.32. A further question (which does not contribute to overall scoring) [26,102] aims to ascertain the extent of relief from currently used analgesics - with improvements seen at Week 6. Baseline perceived analgesic efficacy was 43.5%±17.55, rising to 53.89%±20.0 by Week 6. All participants were confirmed to have FM, reflected in their scores of 25.1±2.86 at baseline (comprised of WPI 15±2.45 and SSS 10.1±1.45). Scores improved to 16.21±5.78 at Week 6 (WPI 9.89±4.21; SSS 6.32±2.54). There is no reported MCID for the 2016 Fibromyalgia Diagnostic Criteria, rather the American College of Rheumatology recommends use as a severity score in the longitudinal evaluation of participants [130]. When using the tool for its primary purpose - a diagnostic tool - almost a third of participants (31.6%, n = 6) experienced an improvement in the order of magnitude that they would have been described as ‘negative’ for FM if we were being assessed for diagnosis for the first time. At the commencement of each calendar week each participant reported an average pain score out of 10 according to the NRS for pain for the preceding 7 days. There was a gradual decline in pain scores during the course of the trial. The average pain score reported at Visit 4 was 6.89. The average pain score reported at the start Week 6 of treatment was 5.86.

3.5.1.3. Fatigue

FSS pre-treatment score was 6.30±0.86, reducing to 5.61±1.16 post-treatment.
3.5.1.4. Sleep disturbance

Following six weeks of PBMT in this study sample, JSQ scores exhibited a reduction from additive score of 17.35±1.90 (mean 4.34±0.97) at baseline to 11.53±6.17 (2.91±1.74) post-treatment. The Jenkins Sleep Questionnaire (JSQ) categorises sleep into ‘little sleep disturbance’ and ‘high frequency of sleep disturbance’ [63]. All participants commenced the trial in the high frequency category, that is, difficulty falling to sleep and staying asleep, waking several times per night, and feeling worn out after their usual night’s sleep. Ten participants (52.6%) fell into the ‘little sleep disturbance’ category post-intervention. Of those that demonstrated better sleep post-treatment (68.4%, n = 13), all improvements were ≥20% (range 20% to 88.9%), with an overall mean improvement of 33.6%.

3.5.1.5. Patient global

Post-treatment, participants were asked to rate the change to their overall quality of life, symptoms, emotions, and activity limitation related to their pain condition. The mean average score was 5.47±1.43. Four participants (21.1%) gave a score of 7. A further question denotes degree of change since commencing the treatment. At Week 6, seventeen participants (89.5%) trended toward ‘much better’, whilst two participants scored ‘no change’. No participant trended towards ‘much worse’. By Week 24, the mean average score was 3.79±2.1, indication that participants remained ‘a little better’ and ‘somewhat better’ at this timepoint. Thirteen participants (68.4%) continued to trend toward ‘much better’, five participants (26.3%) felt no change, and one participant (5.3%) felt worse. Eleven participants (57.9%) had overall benefits in their condition in the order of ‘moderate’ or ‘substantial’ [88], with five participants (26.3%) reporting clinically significant improvements that were still ongoing at 24 weeks.

3.5.2. Core domains: performance-based outcome measures

3.5.2.1. Tenderness

The majority of participants did not tolerate the recommended pressure application of 4kg/cm² [16,133] across most tender points. Results are therefore presented according to the maximum pressure tolerated. Prior to commencement of the trial intervention, participants tolerated an average of 1.21kg/cm²±1.05 across each of the 18 recommended tender points. Post-treatment at Week 6, participants tolerated higher pressures of 1.71kg/cm²±1.16. Average pain scores across 18 tender points (also known as Fibromyalgia Intensity Score or FIS) pre-treatment were 6.35±1.84 compared with 5.17±1.908 post-treatment. Figure 7 depicts the total MTPS score (sum of 18 NRS scores) for the corresponding total pressure tolerated when considering each tender point in isolation. A
A notable change is demonstrated across 17 participants (94.4%). One participant refused to undergo tender point examination post-treatment. Summative total pressure tolerated pre-treatment ranged from 2.57kg/cm\(^2\) to 62.04kg/cm\(^2\), compared with range of tolerated total pressure post-treatment of 6.23kg/cm\(^2\) to 67.25kg/cm\(^2\). Post-treatment, three participants (16.7%) tolerated lower pressures, with the remaining fifteen demonstrating an improvement of 8% to 355% compared with their baseline measurements. Similarly, the ranges for MTPS scores were 72-172 pre-treatment and 37-135 post-treatment, demonstrating 9%-69% reduction in pain scores in thirteen participants (72.2%). Of the remaining five participants with higher post-treatment pain scores, four tolerated a higher
pressure during their examination. **Figure 8** depicts the pressure change for corresponding MTPS score change, with the most optimal result being those participants represented in the top-left hand side of the graph which shows eleven participants (61.1%) tolerated higher pressures for corresponding lower pain scores post-treatment. Objective tenderness measures proved to be consistent with self-report measures compared with ‘fibrofog’ measures in this population (52.6% with complete consistency; 26.3% partial consistency).

**Figure 8.** Percentage change in pressure and pain scores for each participant.

![Graph showing percentage change in pressure and pain scores for each participant.](image)

Y-axis describes percentage change in total pressure tolerated post-treatment at Week 6. X-axis describes percentage change in MTPS (Manual Tender Point Survey) scores post-treatment. Each dot denotes an individual participant.

### 3.5.3. Peripheral domains: participant-reported outcome measures

#### 3.5.3.1. Anxiety and depression

Depression scores post-treatment were $8.21 \pm 3.68$ compared to $12.5 \pm 3.26$ at baseline, representing a 34.3% reduction post-treatment. Similarly, anxiety scores exhibited a 24.8% reduction, being $14 \pm 3.71$ pre-treatment and $10.53 \pm 4.57$ post-treatment. The HADS scale categorises anxiety and depression as mild, moderate and severe. A score $\leq 7$ denotes non-cases [120]. All but one participant suffered with anxiety and depression at the outset of the trial (42.1% ‘severe’ anxiety; 26.3% ‘severe’ depression). Ten participants (52.6%) moved into a lower severity category of anxiety post-treatment, three of which improved by $\geq 2$ categories. Five participants (26.3%) no longer suffered anxiety post-treatment and were classed as ‘non-cases’; one of which commenced the trial in the ‘severe’ category. Post-
treatment, 78.9% participants (n = 15) moved into a milder category of depression than at the trial outset. Five participants (26.3%) improved by ≥2 categories, and 36.8% participants’ (n = 7) depressive symptoms resolved, being classed as ‘non-cases’ post-treatment.

3.5.3.2. Stiffness and dyscognition

Subsections of FIQR were used to assess self-reported stiffness and cognitive impairment ('level of stiffness' and 'level of memory' problems, respectively), comprising of an 11-point NRS score for each. Stiffness pre-treatment was 9.05±1.02, compared with 5.95±2.56 post-treatment. Self-reported dyscognition also demonstrated improvement with a pre-treatment value of 8.35±1.31, compared with 5.58±2.56 post-treatment.

3.5.4. Peripheral domains: performance-based outcome measures

3.5.4.1 Dyscognition

The Stroop Test results are presented according to total correct score and accuracy (%). Total score achieved pre-treatment was 27.4±16.0, compared with 31.21±15.11 post-treatment. Accuracy is similar post-treatment (pre-treatment 85.23±24.06; post-treatment 85.45±24.04). When comparing self-report cognitive impairment to objective measures used, only four participants (21.1%) demonstrated absolute consistency, with a further five participants (26.3%) exhibiting relative consistency. Self-reported memory problems showed an overall mean improvement of 33.2% post-treatment.
**Figure 9.** Box and whisker plots demonstrating improvements following trial intervention for all outcome measures.

3.5.5. **Confidence Intervals and Effect Sizes**

Of the participant-reported outcome measures, all but one demonstrated a large effect size – with the fatigue severity scale and tender point examination showing a medium effect size. Effect size for the Stroop Test was small. Confidence intervals align with this – no confidence interval crosses zero for all participant-reported outcome measures, but do cross zero for performance-based outcome measures. Prior to performing t-tests on the FIQR, Skewness and Kurtosis tests were undertaken which confirmed the data to be in limits of a
normal distribution [45]. 95% Confidence Intervals and Cohen’s $d$ effect sizes are summarised in for Week 6 and Week 24 in Table 7 and Table 8, respectively.

**Table 7.** Mean change pre- and post-trial intervention (Week 6), presented with 95% Confidence Intervals and effect size of change.

<table>
<thead>
<tr>
<th>Outcome Measure</th>
<th>Mean Improvement (95% CI)</th>
<th>Cohen’s $d$ Effect Size</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Participant-reported outcome measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revised Fibromyalgia Impact Questionnaire</td>
<td>24.44 (15.27 to 33.60)*</td>
<td>1.49*</td>
</tr>
<tr>
<td>FIQR Stiffness</td>
<td>3.11 (2.05 to 4.16)</td>
<td>1.59</td>
</tr>
<tr>
<td>FIQR Dyscognition</td>
<td>2.74 (1.48 to 3.99)</td>
<td>1.38</td>
</tr>
<tr>
<td>Brief Pain Inventory – Short Form</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BPI Pain Intensity</td>
<td>3.01 (2.38 to 3.64)</td>
<td>2.37</td>
</tr>
<tr>
<td>BPI Pain Interference</td>
<td>2.35 (1.31 to 3.39)</td>
<td>1.43</td>
</tr>
<tr>
<td>Fibromyalgia Severity Score</td>
<td>8.68 (5.61 to 11.76)</td>
<td>1.95</td>
</tr>
<tr>
<td>Fatigue Severity Scale</td>
<td>0.67 (0.04 to 1.39)</td>
<td>0.68</td>
</tr>
<tr>
<td>Jenkins Sleep Questionnaire</td>
<td>5.68 (2.84 to 8.53)</td>
<td>1.27</td>
</tr>
<tr>
<td>Hospital Anxiety and Depression Score</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HADS-A</td>
<td>3.47 (2.02 to 4.93)</td>
<td>0.83</td>
</tr>
<tr>
<td>HADS-D</td>
<td>4.21 (2.65 to 5.77)</td>
<td>1.23</td>
</tr>
<tr>
<td><strong>Performance-based outcome measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tender Point Examination</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fibromyalgia Intensity Score</td>
<td>1.08 (-0.03 to 2.19)</td>
<td>0.52</td>
</tr>
<tr>
<td>Total Pressure tolerated (kg/cm²)</td>
<td>0.57 (0.16 to 0.99)</td>
<td>0.49</td>
</tr>
<tr>
<td>Stroop Test</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Score</td>
<td>4.11 (0.61 to 7.60)</td>
<td>0.24</td>
</tr>
<tr>
<td>Accuracy (%)</td>
<td>0.70 (-7.21 to 8.61)</td>
<td>0.01</td>
</tr>
</tbody>
</table>

*P = < 0.001

**Table 8.** Mean changes at Week 24, presented with 95% Confidence Intervals and effect size of change.

<table>
<thead>
<tr>
<th>Outcome Measure</th>
<th>Mean Improvement (95% CI)</th>
<th>Cohen’s $d$ Effect Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revised Fibromyalgia Impact Questionnaire</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 6 / Week 24</td>
<td>-10.41 (8.98 to 11.85)*</td>
<td>0.57</td>
</tr>
<tr>
<td>Baseline / Week 24</td>
<td>14.02 (12.55 to 15.49)**</td>
<td>0.94</td>
</tr>
<tr>
<td>Patient Global Impression of Change</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 6 / Week 24</td>
<td>1.68 (1.47 to 1.9)</td>
<td>0.94</td>
</tr>
</tbody>
</table>

*P=0.23, **P=0.001
### 3.5.6. Medication changes

Participants’ medications and dosages were compared before commencing the trial treatment and after completing the course of treatment (Table 9).

<table>
<thead>
<tr>
<th>DRUG CLASS</th>
<th>Reduced (or stopped)</th>
<th>Static</th>
<th>Increased</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paracetamol, n = 6</td>
<td>1 (2)</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Anti-inflammatories, n = 4</td>
<td>1 (1)</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Opioids, n = 17</td>
<td>6 (3)</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td>Tricyclic antidepressants (TCAs), n = 11</td>
<td>1 (1)</td>
<td>8</td>
<td>1</td>
</tr>
<tr>
<td>SSRIs/SNRIs, n = 11</td>
<td>0 (2)</td>
<td>8</td>
<td>1</td>
</tr>
<tr>
<td>Anticonvulsants, n = 11</td>
<td>1 (0)</td>
<td>9</td>
<td>1</td>
</tr>
<tr>
<td>Anxiolytics, n = 3</td>
<td>0</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Sleeping tablets, n = 3</td>
<td>0</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Beta blockers, n = 2</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Migraine prophylaxis and treatment, n = 3</td>
<td>0</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Antipsychotic, n = 1</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>

*n* denotes number of drugs.

At trial outset, 14 participants were taking 17 opioid-based medications. Nine participants (64.3%) reduced or stopped opioid medication by Week 6; including codeine phosphate, co-codamol 30/500, tramadol, Oramorph® and BuTrans® transdermal patch. A considerable number of antidepressants were being taken for the indication of depression (as opposed to neuropathic pain) and as such the dosing of these drug classes did not alter considerably. In particular, four participants were taking SNRIs (serotonin and norepinephrine reuptake inhibitors) in the form of duloxetine for the indication of neuropathic pain at trial outset. Two participants stopped duloxetine by the end of the trial, one of which commenced the trial on the maximum dose of 120mg. Of those taking anticonvulsants for neuropathic pain, it is noteworthy that one participant’s baseline dose was double the maximum daily recommended dose. By Week 6, the dose was within recommended limits. One participant was initiated on quetiapine by their psychiatrist for the indication of insomnia.

### 3.5.7. Power calculation

One of the objectives following this pilot feasibility study is to inform the sample size of a definitive trial. The FIQR is taken to be the primary outcome measure for a RCT. Using Cohen’s $d$ Effect Sizes, power tables for Effect Size $d$ [29] were utilised to ascertain required sample size for a definitive trial. Using a two-tailed $\alpha = 0.01$ and the Cohen’s $d$ Effect Size for FIQR from the study population, 26 participants should be recruited into each arm for a 99% power. Aiming for 30 participants in both groups would allow for a 10% dropout rate in each
group. This is a conservative estimate given the dropout rate in this pilot feasibility trial was <10%. Despite the large effect size obtained, 99% power has been suggested as a conservative estimate in view of the small sample size in this feasibility trial.

In comparison to similar trials looking at the same therapy (albeit, localised modality) in FM participants, a 2019 meta-analysis [134] reports a pooled standardised mean difference of 1.16. Out of the 9 RCTs analysed the range for sample size was between 10 to 25 in each arm. Therefore, based on previous average effect sizes our proposed sample size is in keeping with past work, and again allows for a more conservative estimate.

3.5.8. Harms

Post-treatment physiological parameters did not reveal any adverse effects of treatment.
4. Discussion

The feasibility trial aim was to assess trial and device acceptability for a definitive trial. Participants were satisfied with the provision of information, semi-structured interviews, trial device, and prospect of future placebo treatment. Outcome measures assessed via telephone at Week 24 were well-received, reflected in 100% retention rate at Week 24. Participants found it difficult to adhere to the treatment schedule, primarily due to the nature of their condition. There were uncertain clinical implications of heat exposure and transdermal drug delivery systems. Recruitment was negatively impacted by the number of participants receiving steroid injections. Animal studies have shown reduced anti-inflammatory effects of PBM in those using steroids concomitantly [15]. However, data regarding the degree of hypothalamic-pituitary-adrenal (HPA) axis suppression is inconsistent. For instance, evidence [1] has identified that following steroid injections normal function in the HPA axis returns by day 28. This has implications for eligibility criteria and would increase recruitment for a subsequent trial.

Evidence from meta-analyses focusing on localised PBMT [57,91,134] has demonstrate consistent positive change across psychosocial domains for people with FM. Moreover, no side effects were reported. In the present study, participants’ quality of life improved significantly across time, both statistically and clinically [10]. For the PGIC scale, clinically significant improvements are reported as ‘much improved’ or ‘very much improved’ [31,97], equivalent to a score or 6 or 7 [60]. Our study population gained overall benefits on their quality of life relating to their FM in the order of ‘moderate’ or ‘substantial’ [97] secondary to the trial intervention.

Pain reduction was clinically significant [85,88] with significant improvement in pain-intensity and pain-interference ‘categories’ [79,112]. This demonstrates consistency with the aforementioned FM trials [57,91,134] and was also supported by the reduction in pain-related medication reported in this study. Emerging evidence describes a small-fibre neuropathy associated with FM pain [23]. Systematic reviews and meta-analyses show localised PBMT to be effective in treating neuropathic pain [30]. FM represents a more widespread and resistant form [23], thus lending itself to the whole-body approach. Furthermore, meta-analysis data regarding localised PBMT shows improvements in localised muscle pain [2]. There appears to be a clear advantage in supporting use of whole-body PBMT in the FM population. The current study identified participants having an increased pressure pain threshold across widespread muscle groups following a course of whole-body PBMT – consistent with data from a recent whole-body PBMT RCT [96]. It should be noted that results are subject to how a participant is feeling on a given day [7]. FM is regarded as an unpredictable condition with significant temporal variability in symptoms [65] and this is reflected in the scores. However, the MTPS remains the recommended method for assessing tenderness [16]. Given the current results an update to the recommended applied pressure needs could be considered to a lower value.
Self-reported stiffness demonstrated a clinically significant improvement of 34.3%; more than double the MCID of 13% for FIQ stiffness [10]. A significant improvement in stiffness was observed in localised PBMT meta-analyses in FM patients [134]. Quantification of taut muscle bands in stiffness assessment is one possibility [8], however, there is no consensus regarding standardisation of muscle groups to be assessed. Furthermore, studies do not reliably show that quantitative stiffness correlates to symptom burden in the FM population [48,66]. Recent studies have shown promise in this technique in assessing post-stroke stiffness [110], but further research to validate this technique in the FM population is warranted.

This study population had high baseline fatigue levels, which improved post-treatment but remained in the severe category [77]. The change was twice the MCID [97,106] and consistent with meta-analysis data regarding localised PBMT [134]. Fatigue is multidimensional and its aetiological mechanism is not fully understood [13]. Several recent meta-analyses evaluating localised PBMT in healthy subjects have identified improved fatigued related outcomes [39,44,92,128]. Further research is needed around this for people with FM. With regards to sleep, a recent Cochrane review suggests a JSQ MCID value of 20% [74] – a value which 100% of the study population achieved, with some improvements as high as 90%. Localised PBMT meta-analyses have not explicitly reported on sleep [134]. A study evaluating whole-body PBMT in a group of female athletes resulted in better quality sleep and therefore reduction in quantity of sleep, even after higher training loads [104]. Augmented autonomic profiles seen after whole-body PBMT [96,104] has implications on sleep quality and vice versa [125,139].

The current study illustrates improvements in anxiety and depression more than twice the MCID – taken as a change of 1.7 based on other chronic diseases [80,129]. The aforementioned meta-analyses mirror these improvements [134]. Moreover, recent systematic reviews and meta-analyses have demonstrated significant reductions in anxiety, depression, traumatic brain injury with co-morbid depression, and post-traumatic stress disorder [5,52,108]. There is no standard recommended objective cognitive test for FM patients [9,16]. Our results showed improved processing speed post-treatment, but only with small effect size. Stroop accuracy (surrogate marker of inhibitory control) was unchanged. Assessment is further confounded by heterogeneity in mood levels which are known to impact on cognition [13]. Promising meta-analytic data from using localised PBMT for dementia treatment [107] and for healthy adults [109] is worth noting. Specifically, executive function, memory and selective inattention improved which interestingly are the subdomains with most substantial deficit exhibited in FM patients [9,109]. The improvements seen in our population with regards to sleep, psychological symptoms and cognition may be explained by the superadded central stimulation seen with whole-body PBMT, whereby sufficient brain penetration is achieved to improve sleep and other psychological factors [5,52,96,108].
From a biochemical viewpoint, mitochondrial dysfunction with resultant increase in reactive oxygen species (ROS) underpin FM pathogenesis [30,37,135]. There is reduced oxygen supply to muscles secondary to reduction in capillary quantity and function [37]. Suggested therapeutic strategies should therefore specifically target reducing oxidative stress [30,119].

PBM light (red and near infrared) comprise optimal wavelengths to achieve both tissue penetration and absorption at a mitochondrial level, ultimately reducing oxidative stress and increasing adenosine triphosphate (ATP) synthesis. Downstream effects are chemotactic, neural, lymphatic and humoral – culminating in improved blood flow and oxygen delivery, reduced oedema and improved tissue repair, anti-inflammatory and analgesic effects [36]. In healthy subjects, meta-analyses show reduced lactate levels and other biomarkers of post-exercise muscle damage following both localised and whole-body PBMT [44,76,92,137]. The potential to improve muscle functioning and recovery may explain why important factors such as pain interference and ability to cope has significantly improved in our population.

Several limitations are acknowledged from the current results. Standard design and bias limitations associated with feasibility studies are accepted. Trial duration spanned four seasons hence weather as a variable could not be standardised and weather can affect FM severity [17,53,55,129]. We did not control for pain catastrophizing, however it is a factor that maintains chronic pain and predicts a poorer response to treatment [32,83]. Our data may not be not representative of the FM population in general. The reason for this is past population studies [11,121] identify a lower baseline score. This suggests our study could have included participants with more severe cases of FM. A future national multicentre trial will give a better understanding of baseline severity in those participants being treated under a secondary care pain clinic.

4.1. Recommendations for future research and clinical implications

We recommend the FIQR as the primary outcome measure for a future definitive trial. The original FIQ is the primary outcome measure in many FM trials [134]. It is specific to FM and it is simple to interpret - giving one overall figure which encompasses function, overall impact and symptoms of FM. Moreover, FIQR correlates directly with the original FIQ [11], so is comparable not only with present and future scores, but also with historical FIQ scores.

From a clinical viewpoint, we cannot ignore the wealth of recent clinical guidelines from national and international governing bodies recommending use of PBMT for various painful conditions: World Health Organization [54], International Association for the Study of Pain [61], NICE [95], American College of Physicians [103], and British Medical Journal [14]. NICE acknowledge the short-term clinical utility and safety of localised PBMT for chronic primary pain and recommend assessment of effectiveness of PBMT on sleep, pain interference and physical function, long-term effectiveness, and assessment of cost-effectiveness [93]. The present study demonstrates improvements in all but cost-effectiveness, which was not assessed. Cost-effectiveness so far is promising and has been demonstrated for use of PBMT.
in oral mucositis and myofascial temporomandibular disorders [20,67,114]. The definitive trial should consider incorporating participants receiving steroid therapy and undergoing separate sub-group analyses. Participants should potentially be presented with a choice of two treatment schedules to introduce a degree of flexibility.

5. Conclusions

Findings indicate high acceptability of trial device and procedures. This pioneering work represents a well-designed feasibility trial that has shown significant improvements in all fibromyalgia domains in the short- and long-term. Future research will be guided by the updated Medical Research Council and National Institute for Health Research [113]. In a condition renowned for its shortfall in efficacious treatments, we now owe it to our patients to pursue the real-world approach towards widely instituting this safe, non-invasive treatment. The remaining questions to be answered are whether this is truly more effective and cost-effective than usual care.

Conflict of interest statement

The authors have no conflicts of interest to declare.

Acknowledgements

This work was supported by the Clinical Research Facility at Sandwell and West Birmingham NHS Trust. The authors would like to thank the Patient and Public Involvement and Engagement Group, in particular N.G. who is a member of the Trial Steering Committee. The authors thank Dr Catherine Browne, Dr Mohamed Ibrahim, Dr Shabnam Salim, Dr Supriya Antrolikal, Dr Akhil Srinivasa and Dr Mahesh Eddula for their work in the data collection phase of the trial.
References


[18]. Braun V, Clarke V. Reflecting on reflexive thematic analysis. *Qual Res Sport Exerc Health* 2019;11(4):589-597


[34]. de Andrade AL, Bossini PS, Parizotto NA. Use of low level laser therapy to control neuropathic pain: A systematic review. *J Photochem Photobiol B* 2016; 164: 36-42


[112]. Sim J, Lewis M. The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency. *J Clin Epidemiol* 2012;65(3):301-8


[117]. Snaith RP. The Hospital Anxiety And Depression Scale. *Health Qual Life Outcomes* 2003;1:29

[118]. Stern AF. The hospital anxiety and depression scale. *Occup Med (Lond)* 2014;64(5):393-4


[120]. Surendran S, Mithun CB. FRIO647 Estimation of minimum clinically important difference in fibromyalgia for fior using bpi as the anchor measure. *Ann Rheum Dis* 2018;77(Suppl 2):845-845


[137]. Zagatto AM, Dutra YM, Lira FS, Antunes BM, Faustini JB, Malta ES, Lopes VHF, de Poli RAB, Brisola GMP, Dos Santos GV, Rodrigues FM, Ferraresi C. Full Body Photobiomodulation Therapy to
